Sort   by:  
 Page size 
In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no clinically useful marker that predicts response. A major ...
ORGANISM(S): Homo sapiens 
The molecular mechanisms of clinical response or resistance to therapy were evaluated in colorectal cancer patients in a prospective biomarker discovery project. Rectal adenocarcinomas, biopsied before (diagnostic biopsy) and after (surgical resection) pre-operative short-course radiotherapy [RT] or...
ORGANISM(S): Homo sapiens 
As metabolic rewiring is crucial for cancer cell proliferation, metabolic phenotyping of patient-derived organoids is desirable to identify drug-induced changes and trace metabolic vulnerabilities of tumor subtypes. We established a novel protocol for metabolomic and lipidomic profiling of colorecta...
2021-10-12 | MTBLS2130 | MetaboLights

KRAS-mutant colorectal cancer (KRASmut CRC) exhibits metabolic plasticity and chemoresistance, but the underlying mechanisms remain incompletely understood. Here, we show in CRC cells and organoids that KRAS-driven lactate accumulation promotes MCT1 K224 lactylation, which stabilizes mitochondria...

2026-10-16 | MTBLS16037 | MetaboLights
KRAS-mutant colorectal cancer (KRASmut CRC) exhibits metabolic plasticity and chemoresistance, but the underlying mechanisms remain incompletely understood. Here, we show in CRC cells and organoids that KRAS-driven lactate accumulation promotes MCT1 K224 lactylation, which stabilizes mitochondrial M...
2026-10-16 | MTBLS16034 | MetaboLights
Sort   by:  
 Page size